Efzofitimod 3 mg/kg ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 84 | Sarcoidosis | 1 |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05415137 (ClinicalTrials.gov) | September 15, 2022 | 8/6/2022 | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: Efzofitimod 3 mg/kg;Drug: Efzofitimod 5 mg/kg;Drug: Placebo | aTyr Pharma, Inc. | Kyorin Pharmaceutical Co.,Ltd | Recruiting | 18 Years | 75 Years | All | 264 | Phase 3 | United States;Japan;Netherlands;Puerto Rico;Spain |